Preview
Therapy for acute myocardial infarction has its most compelling effect when the patient is seen early in the course of illness. In this article, the authors discuss the status of nonlytic medications during the acute phase of Q-wave infarction and also examine the role of risk modification and stratification in long-term survival of the patient.